How many patients with advanced or metastatic cancer respond to immunotherapy (checkpoint inhibitors)?

Our new paper in the International Journal of Cancer tackles this question, led by @AlysonHaslam with @VPrasadMDMPH

🧵 1/8 First, check Table 1: the number of immunotherapy compounds—anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-LAG-3...

➡️ A lot of 'me-too' drugs in this space.
2/8

Our new work is out in EJC, led by @AlysonHaslam, with @SruthiRanganat1 and @VPrasadMDMPH!

We argue against the routine use of CDK4/6 inhibitors as adjuvant therapy in ER+ /HER2- early breast cancer

See why in this thread !🧵1/7
paper here : sciencedirect.com/science/articl… First: the iDFS gain are fragile, with questionable reliability

We noted an imbalance in early drop-out, with potential for informative censoring. This is detailed here:

In short, with slight assumptions, the benefit is no longer significant👇
2/

https://x.com/Timothee_MD/status/1773773752855040481

Hey #ASCO2023, keep following !

Let's have a 👀 at the LUNAR phase 3 trial,
showing an OS benefit with tumor treating fields (TTFs) in addition to SoC in platinum refractory meta NSCLC❗️

3.3 months median OS improvement,
Wow... a new SoC ❓

A few thoughts🧵👇
1/7 First the design :
OPEN LABEL 👇

+again and again, a restricted physician's choice
(see our work here : bit.ly/3DsYqPx)

but let's be fair, it's the same in both arms
2/7

Some toughts about the INDIGO phase 3 trial, vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #ASCO2023

- setting = residual or recurrent disease
- primary EP = PFS = improved from 11.1 to 27.7 Mo (16.6)

Here are some toughts 🧵
1/6 First, we can see that median time from diagnosis ≥ 2.5 years in both groups, so it really looks like mostly recurrent disease.

Now let's make some comparison with another trial, the "PCV trial" -->
This trial was in first-line patients ❗️
2/6